论文部分内容阅读
目的:观察参芪扶正注射液辅助治疗中晚期胃癌(脾胃虚寒证)的临床疗效及其对血清肿瘤标志物水平的影响。方法:将我院中医科收治的中晚期胃癌患者62例随机分为两组,每组31例,对照组行FOLFOX4常规化疗方案治疗;治疗组在对照组治疗基础上结合参芪扶正注射液治疗,治疗后比较两组患者临床疗效、血清肿瘤标志物变化情况(TNF-a、CEA、CA19-9、CA72-4)及患者生活质量(采用Spitzer法)等指标。结果:疗程结束后,治疗组临床总有效率为61.3%,明显高于对照组的45.2%,且治疗组患者治疗后生活质量改善情况明显优于对照组,两组比较差异均有统计学意义(P<0.05);两组患者治疗后CEA、CA19-9、CA72-4均较治疗前下降,然治疗组患者相关肿瘤标志物水平下降更显著,两组比较差异有统计学意义(P<0.05)。结论:参芪扶正注射液辅助治疗中晚期胃癌(脾胃虚寒证)患者临床疗效可靠,可有效降低相关血清肿瘤标志物水平,提高患者生活质量,改善患者远期预后。
Objective: To observe the clinical efficacy of Shenqi Fuzheng injection in adjuvant treatment of advanced gastric cancer (spleen and stomach syndrome) and its effect on the level of serum tumor markers. Methods: Sixty-two patients with advanced gastric cancer admitted to our hospital were randomly divided into two groups (31 in each group). The control group was treated with FOLFOX4 routine chemotherapy regimen. The treatment group was treated with Shenqi Fuzheng Injection on the basis of the control group After treatment, the clinical efficacy, serum tumor markers (TNF-a, CEA, CA19-9, CA72-4) and quality of life (Spitzer method) were compared between the two groups. Results: After treatment, the total clinical effective rate was 61.3% in the treatment group, which was significantly higher than 45.2% in the control group, and the quality of life improvement of the treatment group was obviously better than that of the control group after treatment, the difference was statistically significant (P <0.05). After treatment, CEA, CA19-9 and CA72-4 in both groups decreased compared with those before treatment, while the levels of related tumor markers in treatment group decreased more significantly (P < 0.05). Conclusion: Shenqi Fuzheng injection in the treatment of advanced gastric cancer (spleen and stomach Deficiency Syndrome) patients with reliable clinical efficacy, can effectively reduce the level of serum tumor markers, improve patient quality of life and improve long-term prognosis of patients.